Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I/II trial assessing new intranasal corona vaccine

Next Previous
Search
Trial Profile

A phase I/II trial assessing new intranasal corona vaccine

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 07 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NANOVAC (Primary)
  • Indications Coronavirus infections; COVID 2019 infections
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 07 Jan 2022 New trial record
    • 05 Jan 2022 According to Intravacc media release, this study is led by Dr Leo Visser of the Infectious Diseases Department of the LUMC and is expected to start at the end of 2022 with first study data expected in the first half of 2023.
    • 05 Jan 2022 According to Intravacc media release, the company announced a partnership with Dutch Leiden University Medical Center (LUMC) to develop and evaluate a new nasal spray corona vaccine in this trial, financing of this study is made possible in part by the Top Consortium for Knowledge and Innovation (TKI) of Health Holland, part of the Dutch top sector Life Sciences & Health.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top